Aroa Biosurgery Ltd
ASX:ARX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.375
0.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Aroa Biosurgery Ltd
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.
Cash Flow: Aroa Biosurgery posted its fourth consecutive quarter of positive net cash flow, with operating cash flow of $2.1 million.
Cash Position: Cash increased by $1.3 million, closing the quarter at $23.4 million.
Sales Growth: Total cash receipts from customers reached $23.5 million, with strong performance across the direct team and TELA Bio.
Myriad Performance: Record Myriad sales, up over 30% year-on-year for the quarter, are driving growth and momentum.
Guidance Reiterated: Management reaffirmed revenue and normalized EBITDA guidance for the full year.
Symphony Update: Patient recruitment is complete for the Symphony RCT, with results expected to support US reimbursement.
US Market: Pending US reimbursement changes and potential government shutdown introduce some uncertainty, but management is confident in its positioning.
Future Plans: Small increase in sales staff planned, focus remains on productivity and deeper account penetration.
